Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19 patients: A retrospective two center study in Saudi Arabia
AlQadheeb et al.
, Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19..
, Clinical Infection in Practice, doi:10.1016/j.clinpr.2023.100229
Retrospective 848 ICU patients in Saudi Arabia, showing lower mortality with HCQ in unadjusted results.
risk of death, 34.8% lower, RR 0.65, p < 0.001, treatment 37 of 92 (40.2%), control 466 of 756 (61.6%), NNT 4.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
AlQadheeb et al., 10 May 2023, retrospective, Saudi Arabia, peer-reviewed, mean age 55.8, 9 authors, study period March 2020 - August 2021.
Abstract: Clinical Infection in Practice 19 (2023) 100229
Contents lists available at ScienceDirect
Clinical Infection in Practice
journal homepage: www.sciencedirect.com/journal/clinical-infection-in-practice
Practical clinical reviews
Impact of common comorbidities on antimicrobial consumption and
mortality amongst critically ill COVID-19 patients: A retrospective two
center study in Saudi Arabia
Nada AlQadheeb a, *, Hanine AlMubayedh b, Sarah AlBadrani b, Abdul Salam c,
Mukhtar AlOmar a, Ahmed AlAswad d, Mohammed AlMualim d, Zahra AlQamariat e,
Rasheed AlHubail f
Pharmacy Department, King Fahad Specialist Hospital, Eastern Province, Saudi Arabia
College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Eastern Province, Saudi Arabia
Department of Biostatistics and Epidemiology, King Fahad Specialist Hospital, Eastern Province, Saudi Arabia
Critical Care Department, Qatif Central Hospital, Eastern Province, Saudi Arabia
Pharmacy Department, Dammam Medical Complex, Eastern Province, Saudi Arabia
Critical Care Department, Dammam Medical Complex, Eastern Province, Saudi Arabia
A R T I C L E I N F O
A B S T R A C T
Intensive care unit
Objectives: To determine the association between common comorbidities, ICU mortality and antimicrobial con
sumption among critically ill COVID 19 patients in Saudi Arabia.
Methods: A retrospective observational study of patients admitted to the ICU from March 1st, 2020, through
August 31st, 2021. We excluded patients who stayed <24 h in the ICU and with no confirmed COVID-19 PCR
Results: Of the 976 screened ICU patients, 848 were included. While there was no difference in mortality between
patients with and without comorbidities, those with at least one comorbidity had a higher severity of illness (p =
0.013). Compared to survivors, non-survivors were more likely to require mechanical ventilation and vasopressor
support (P < 0.001). Almost all patients received at least one antimicrobial therapy. Predictors independently
associated with ICU mortality were: older age (adjusted odds ratio [AOR], 1.03; 95% confidence interval [CI],
1.01–1.04), vancomycin use (AOR, 2.69; 95% [CI], 1.65–4.37), linezolid use (AOR, 2.65; 95% [CI], 1.65–4.04),
sepsis or septic shock (AOR, 6.39; 95% [CI], 3.68–11.08), Acute Kidney Injury (AKI) (AOR, 2.51; 95% [CI],
1.61–3.92) and Acute Respiratory Distress Syndrome (ARDS) (AOR, 2.03; 95% [CI], 1.61–3.92).
Conclusion: Older age, vancomycin and linezolid use, sepsis/septic shock, AKI, and ARDS were negative prog
nostic factors in critically ill COVID-19 patients. More studies are needed to evaluate the outcomes of survived
critically ill patients in relation to their vaccination status.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.